These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 852589)

  • 41. Altered pattern of dopa metabolism.
    Fellman JH; Roth ES; Heriza EL; Fujita TS
    Biochem Pharmacol; 1976 Jan; 25(2):222-3. PubMed ID: 1259789
    [No Abstract]   [Full Text] [Related]  

  • 42. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 43. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urinary excretion of noradrenaline after treatment with alpha-methyldopa: inhibition by a central nervous mechanism.
    Andén NE; Henning M
    Acta Physiol Scand; 1974 Jan; 90(1):69-72. PubMed ID: 4814544
    [No Abstract]   [Full Text] [Related]  

  • 45. New pathway for metabolism of dopa.
    O'Leary MH; Baughn RL
    Nature; 1975 Jan; 253(5486):52-3. PubMed ID: 1167399
    [No Abstract]   [Full Text] [Related]  

  • 46. Studies on the enzymatic blood-brain barrier: quantitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions.
    Hardebo JE; Falck B; Owman C; Rosengren E
    Acta Physiol Scand; 1979 Apr; 105(4):453-60. PubMed ID: 452922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple roles of the active site lysine of Dopa decarboxylase.
    Bertoldi M; Voltattorni CB
    Arch Biochem Biophys; 2009 Aug; 488(2):130-9. PubMed ID: 19580779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
    Wafa LA; Cheng H; Plaa N; Ghaidi F; Fukumoto T; Fazli L; Gleave ME; Cox ME; Rennie PS
    Int J Cancer; 2012 Jun; 130(12):2835-44. PubMed ID: 21780103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopa decarboxylase in medullary carcinoma of the thyroid.
    Atkins FL; Beaven MA; Keiser HR
    N Engl J Med; 1973 Sep; 289(11):545-8. PubMed ID: 4146664
    [No Abstract]   [Full Text] [Related]  

  • 50. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
    Goshima Y; Nakamura S; Misu Y
    J Pharmacol Exp Ther; 1991 Aug; 258(2):466-71. PubMed ID: 1865350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Interaction of dopa decarboxylase from swine kidney with thiosemicarbazone].
    Minelli A; Borri-Voltattorni C
    Boll Soc Ital Biol Sper; 1974 Jul; 50(12):852-5. PubMed ID: 4475594
    [No Abstract]   [Full Text] [Related]  

  • 52. Chronic toxicity of carboethoxyphthalazinohydrazine and its influence on the excretion of 5-hydroxyindoleacetic acid and the activity of 5-htp-decarboxylase in white rats.
    Chruściel M
    Br J Pharmacol Chemother; 1968 Jan; 32(1):104-12. PubMed ID: 5640168
    [No Abstract]   [Full Text] [Related]  

  • 53. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain.
    Cumming P; Ase A; Laliberté C; Kuwabara H; Gjedde A
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1254-60. PubMed ID: 9390657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
    Melamed E; Hefti F; Bitton V; Globus M
    Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
    Koziel H; Kuran W; Zakrzewska F
    Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
    [No Abstract]   [Full Text] [Related]  

  • 56. Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man.
    Vickers S; Stuart EK; Bianchine JR; Hucker HB; Jaffe ME; Rhodes RE; Vandenheuvel WJ
    Drug Metab Dispos; 1974; 2(1):9-22. PubMed ID: 4150141
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of aromatic L-amino acid decarboxylase by coenzyme-amino acid adducts.
    Rudd EA; Thanassi JW
    Biochemistry; 1981 Dec; 20(26):7469-75. PubMed ID: 7326239
    [No Abstract]   [Full Text] [Related]  

  • 59. Fluctuations in DOPA decarboxylase activity with age.
    Awapara J; Saine S
    J Neurochem; 1975 Apr; 24(4):817-8. PubMed ID: 1123640
    [No Abstract]   [Full Text] [Related]  

  • 60. A kinetic analysis of Drosophila melanogaster dopa decarboxylase.
    Black BC; Smarrelli J
    Biochim Biophys Acta; 1986 Mar; 870(1):31-40. PubMed ID: 3081033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.